This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Inflammation				
Asthma; inflammation	Chitinase 3-like 1 (CHI3L1; YKL40)	<p>A study in mice suggests that inhibiting CHI3L1 could be useful for treating inflammation-associated conditions such as asthma. In an allergen-sensitized mouse model of inflammation, <i>Chi3l1</i> knockout lowered eosinophil, lymphocyte and neutrophil levels and increased macrophage recruitment compared with what was seen in wild-type controls. Next steps include evaluating the extent to which CHI3L1 levels need to be lowered to have a therapeutic effect and monitoring for potential adverse effects.</p> <p>SciBX 2(19); doi:10.1038/scibx.2009.797 Published online May 14, 2009</p>	<p>Patented for use in inflammation-associated conditions including asthma; available for licensing from the Yale University Office of Cooperative Research</p> <p>Contact: John Puziss, Yale University, New Haven, Conn. phone: 203-376-6454 e-mail: john.puziss@yale.edu</p>	<p>Lee, C.G. <i>et al. J. Exp. Med.</i>; published online May 4, 2009; doi:10.1084/jem.20081271</p> <p>Contact: Jack A. Elias, Yale University School of Medicine, New Haven, Conn. e-mail: Jack.elias@yale.edu</p>